TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32959586

Group type: EXPERIMENTAL
Intervention: Ginger-separated moxibustion and Chinese herbal medicine atomization
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ambroxol hydrochloride oral solution and compound methoxynamine capsules, with salbutamol aerosol
Number of subjects: 90
Study: 36084899

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT), details on dosage and duration not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT, remotely-delivered intervention
Number of subjects: 0
Study: 33250326

Group type: EXPERIMENTAL
Intervention: Multidisciplinary group pain program
Number of subjects: 56
Study: 34643650

Group type: EXPERIMENTAL
Intervention: Abatacept (125 mg weekly from weeks 12 to 39)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Ustekinumab (45 mg or 90 mg at weeks 0 and 4, then at weeks 16 and 28)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 108

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 32332962

Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 156

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 156

Group type: COMPARATOR
Intervention: Mepivacaine
Number of subjects: 156
Study: 35775789

Group type: EXPERIMENTAL
Intervention: GLB-TBI intervention (12-month, 22-session program)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: GLB-TBI compliant group (≥80% attendance; ≥85% self-monitoring; n = 10)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: GLB-TBI noncompliant group (n = 17)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Attention control group (n = 27)
Number of subjects: 54
Study: 32911979

Group type: EXPERIMENTAL
Intervention: Staged excision with circumferential margin control (SECMC)
Number of subjects: 102
Study: 32321764

Group type: EXPERIMENTAL
Intervention: 5 IFCN criteria in sensor space
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Analysis in source space
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Expert scoring
Number of subjects: 100
Study: 35961647

Group type: EXPERIMENTAL
Intervention: Instrument-Assisted Soft Tissue Mobilization (IASTM)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Therapeutic Cupping (TC)
Number of subjects: 33
Study: 34090504

Group type: EXPERIMENTAL
Intervention: Ivermectin (Stromectol®‐0.15 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0
Study: 33177145

Group type: EXPERIMENTAL
Intervention: Awake prone positioning (PP) and nasal high flow therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical treatment and nasal high flow therapy
Number of subjects: 0
Study: 36162006

Group type: EXPERIMENTAL
Intervention: Instagram posts
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Twitter posts
Number of subjects: 1000
Study: 34225517

Group type: EXPERIMENTAL
Intervention: MDT treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 60
Study: 36274662

Group type: EXPERIMENTAL
Intervention: Malva Sylvestris cream applied twice a day for up to 14 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 60
Study: 33646303

Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (15 mg/m2 daily IV for 3 consecutive days) plus recombinant human thrombopoietin (300 U/kg daily)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Decitabine alone
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Low-dose decitabine
Number of subjects: 91
Study: 32534942

Group type: EXPERIMENTAL
Intervention: SCORE chart
Number of subjects: 6811

Group type: COMPARATOR
Intervention: High and very high-risk categories identified by SCORE
Number of subjects: 6811
Study: 34232115

Group type: EXPERIMENTAL
Intervention: Solution-focused brief therapy (SFBT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 50
Study: 33853071

Group type: EXPERIMENTAL
Intervention: Mental imagery condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard repeated encoding condition
Number of subjects: 60
Study: 35637845

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion combined with rehabilitation training (RHT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Acupuncture-moxibustion alone
Number of subjects: 150
Study: 34130387

Group type: COMPARATOR
Intervention: Single-dart anesthesia induction protocol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Staged two-dart anesthesia induction protocol
Number of subjects: 14
Study: 34697392

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 949

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study: 36305354

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every 2 weeks (q2w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks (q2w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33241297

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 27
Study: 35277168

Group type: EXPERIMENTAL
Intervention: Liraglutide treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lifestyle counseling
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Baseline Gal-3 levels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gal-3 levels
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of baseline sST2 levels
Number of subjects: 40
Study: 33801514

Group type: EXPERIMENTAL
Intervention: Disaster prevention education with weekly exercise
Number of subjects: 97

Group type: COMPARATOR
Intervention: Traditional exercise education with weekly exercise
Number of subjects: 97
Study: 32515413

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Essential Oils (EO)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride (CPC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 180
Study: 34271146

Group type: EXPERIMENTAL
Intervention: Natural Language Processing (NLP)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Manual chart review
Number of subjects: 435
Study: 33515331

Group type: EXPERIMENTAL
Intervention: Rigid-brace treatment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Subsequent vertebral fractures
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) for low back pain
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Quality of Life and Function Scores
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Annual incidence of subsequent vertebral fracture
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Time to subsequent fractures
Number of subjects: 225
Study: 35283439

Group type: EXPERIMENTAL
Intervention: WeChat messaging with daily individualized guidance
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine guidance only
Number of subjects: 150
Study: 33686683

Group type: EXPERIMENTAL
Intervention: Z-BUF-RL (Ringer's lactate)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Z-BUF-R (Ringer's)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Z-BUF-NS (Normal saline)
Number of subjects: 90
Study: 36197213

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training with intensity controlled by biometric data (heart rate or RPE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Robot-assisted gait training with intensity controlled by therapist's subjective judgment
Number of subjects: 55
Study: 34519439

Group type: COMPARATOR
Intervention: BCAA (2×7 g/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Glycine (2×7 g/day)
Number of subjects: 36
Study: 32871891

Group type: EXPERIMENTAL
Intervention: 1000 IU of Vitamin D daily for 15 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: 200 IU of Vitamin D daily for 15 weeks
Number of subjects: 150
Study: 35238614

Group type: EXPERIMENTAL
Intervention: Phlebotomy group (500 mL bloodletting at baseline and after 6 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Phlebotomy group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 33448139

Group type: EXPERIMENTAL
Intervention: Serum biochemical indexes (ALP, TP, Glu)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Tumor markers (AFP, CA 125, CA199, HE4)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Cytokines (VEGF, TNF‐α, IL‐6, sflt‐1, MCP‐1)
Number of subjects: 190
Study: 32442523

Group type: EXPERIMENTAL
Intervention: sIPV-bOPV-bOPV (1sIPV+2bOPV group)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: sIPV-sIPV-bOPV (2sIPV+1bOPV group)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: sIPV-sIPV-sIPV (3sIPV group)
Number of subjects: 528
Study: 35314636

Group type: EXPERIMENTAL
Intervention: Volume-based modified Lund-Mackay score (VMLMs)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Traditional Lund-Mackay score (TLMs)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SNOT-22
Number of subjects: 50

Group type: COMPARATOR
Intervention: Semi-supervised learning with convolutional neural networks
Number of subjects: 50
Study: 34384991

Group type: EXPERIMENTAL
Intervention: AS reduction intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Repeated contact control condition
Number of subjects: 118
Study: 35795713

Group type: EXPERIMENTAL
Intervention: BNT162b2 as second dose (interventional group)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Control group (no vaccine initially, then BNT162b2 as second dose)
Number of subjects: 664
Study: 34316173

Group type: EXPERIMENTAL
Intervention: Neurogol syrup (a combination of valerian and lemon balm) with quetiapine, 5 mL every 12 hours for five consecutive days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo with quetiapine, 5 mL every 12 hours for five consecutive days
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Neurogol syrup (a combination of valerian and lemon balm) with quetiapine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo with quetiapine
Number of subjects: 53
Study: 32815405

Group type: EXPERIMENTAL
Intervention: Dermal/Epidermal Substitute (Nevelia)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard of care (Control Group)
Number of subjects: 15
Study: 36175996

Group type: EXPERIMENTAL
Intervention: e-coachER intervention
Number of subjects: 450

Group type: COMPARATOR
Intervention: ERS alone
Number of subjects: 450
Study: 33058419

Group type: EXPERIMENTAL
Intervention: Orthodontic Aligners (OA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fixed Appliance (FA)
Number of subjects: 39
Study: 32609946

Group type: EXPERIMENTAL
Intervention: Nasal high-frequency percussive ventilation (nHFPV)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 49
Study: 35067340

Group type: EXPERIMENTAL
Intervention: Composite of all-cause death or unplanned cardiovascular hospitalization within 30 days of presentation
Number of subjects: 0
Study: 33934070

Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy (TCZm)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Logistic regression model on bDMARDm patients
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Extended variable set with regularization
Number of subjects: 452
Study: 32646823

Group type: EXPERIMENTAL
Intervention: PACE Steps to Success program (1-year train-the-trainer program for palliative care integration)
Number of subjects: 551
Study: 35397289

Group type: EXPERIMENTAL
Intervention: Repeat infusion of autologous bone marrow
Number of subjects: 6
Study: 33361473

Group type: EXPERIMENTAL
Intervention: Immediate intervention (Group Lifestyle Balance Program)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Delayed-delivery intervention (control)
Number of subjects: 322
Study: 35451612

Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE treatment at 7.4 GBq at 10 ± 2-week intervals until a predefined radiation dose to the kidneys was reached.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE treatment
Number of subjects: 96
Study: 33306679

Group type: EXPERIMENTAL
Intervention: Primed with a question about COVID-19
Number of subjects: 200

Group type: COMPARATOR
Intervention: No prior contact (Control)
Number of subjects: 200
Study: 33947374

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic supportive psychotherapy (SPSP)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Continuing the initial treatment with the same therapist
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Continuing the initial treatment with another therapist
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Continuing the other type of treatment with another therapist
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance, treatment integrity, and therapist allegiance
Number of subjects: 308
Study: 33386040

Group type: EXPERIMENTAL
Intervention: PRF adjunct (PRF group, PG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Extraction therapy only (spontaneous healing group, SHG)
Number of subjects: 40
Study: 36162789

Group type: EXPERIMENTAL
Intervention: High pain group (observed model expressing higher pain scores)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low pain group (control condition, observed model expressing lower pain scores)
Number of subjects: 0
Study: 33982141

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) 24 IU twice daily for 4 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 95
Study: 33202849

Group type: EXPERIMENTAL
Intervention: Mindfulness-based social intervention program (12-week meditation training)
Number of subjects: 0
Study: 36005910

Group type: EXPERIMENTAL
Intervention: Distal radial approach
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional radial approach
Number of subjects: 250
Study: 33627708

Group type: EXPERIMENTAL
Intervention: 60 minutes of vigorous exercise at 60% max
Number of subjects: 0
Study: 32936872

Group type: EXPERIMENTAL
Intervention: Unrefined carbohydrate diet
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Simple carbohydrate diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: All diets
Number of subjects: 11
Study: 35675275

Group type: EXPERIMENTAL
Intervention: 15-minutes morning light treatment per day for four weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 30-minutes morning light treatment per day for four weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 60-minutes morning light treatment per day for four weeks
Number of subjects: 66
Study: 33115965

Group type: EXPERIMENTAL
Intervention: LCT/MCT propofol
Number of subjects: 129

Group type: COMPARATOR
Intervention: LCT propofol
Number of subjects: 129
Study: 32711674

Group type: EXPERIMENTAL
Intervention: SENTIA (new measuring instrument for assessing suicidal behavior)
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: SENTIA
Number of subjects: 1790
Study: 35294813

Group type: EXPERIMENTAL
Intervention: Iberdomide 0.45 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Iberdomide 0.30 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Iberdomide 0.15 mg
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 34269747

Group type: EXPERIMENTAL
Intervention: Corticospinal tract fractional anisotropy asymmetry (FAasym)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate LASSO model including baseline CST FAasym, age, and UE Fugl‐Meyer
Number of subjects: 0
Study: 35429404

Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Targeted intervention
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 456
Study: 33764084

Group type: EXPERIMENTAL
Intervention: OurRelationship (OR) program
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: ePREP program
Number of subjects: 934

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 934
Study: 32254003

Group type: EXPERIMENTAL
Intervention: Addiction Severity Index (ASI‐psych) score
Number of subjects: 1660
Study: 36256856

Group type: EXPERIMENTAL
Intervention: Good Behaviour Game (GBG)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 731
Study: 34275690

Group type: EXPERIMENTAL
Intervention: Primarily Joint
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Mixed MoU
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Primarily Pipe
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Primarily Blunt
Number of subjects: 302
Study: 35401282

Group type: EXPERIMENTAL
Intervention: COMT rs4680 met allele
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Exploratory GWAS for change in pain frequency
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Exploratory GWAS for change in pain severity
Number of subjects: 212
Study: 33831369

Group type: EXPERIMENTAL
Intervention: 1.0 M DMSO cryopreserved testicular cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal transplantation of recovered cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sperm collected from recipients
Number of subjects: 0
Study: 35191766

Group type: EXPERIMENTAL
Intervention: Developmental bibliotherapy using 54 selected materials from the DBMD for 6 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Developmental bibliotherapy
Number of subjects: 64
Study: 33663489

Group type: EXPERIMENTAL
Intervention: Nomogram based on multivariable model including type 2 diabetes mellitus (T2DM), microangiopathy, history of congestive heart failure (CHF), history of hypertension, diastolic blood pressure (DBP), urine output, Glasgow coma scale (GCS), and respiratory rate (RR).
Number of subjects: 760
Study: 35724304

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 1536
Study: 32549142

Group type: EXPERIMENTAL
Intervention: School-based intervention program promoting healthy eating habits for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35397664

Group type: EXPERIMENTAL
Intervention: Rucaparib (oral poly(ADP‐ribose) polymerase inhibitor)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 458
Study: 32210349

Group type: EXPERIMENTAL
Intervention: Fe-PA-HCP in bouillon without inhibitory matrix
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fe-PA-HCP in bouillon with inhibitory matrix
Number of subjects: 22

Group type: COMPARATOR
Intervention: FeSO4 in bouillon
Number of subjects: 22

Group type: COMPARATOR
Intervention: FePP in bouillon
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fe-PA-HCP with inhibitory meal
Number of subjects: 22

Group type: COMPARATOR
Intervention: FePP with inhibitory meal
Number of subjects: 22
Study: 33450335

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 313

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Severe AKI (overall)
Number of subjects: 313
Study: 33225663

Group type: COMPARATOR
Intervention: Intralesional sodium Stibogluconate (1-5 ml depending on lesion size, 100 mg/ml)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Combination therapy of oral Allopurinol (20 mg/kg/day in divided doses) and intralesional sodium Stibogluconate (1-5 ml depending on lesion size, 100 mg/ml)
Number of subjects: 164
Study: 34897499

Group type: EXPERIMENTAL
Intervention: Abatacept + MTX ≤8 mg/week
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Abatacept + MTX >8 mg/week
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo + MTX ≤8 mg/week
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo + MTX >8 mg/week
Number of subjects: 401
Study: 34139861

Group type: EXPERIMENTAL
Intervention: Congenital heart disease (CHD) patients
Number of subjects: 88700

Group type: COMPARATOR
Intervention: Matched controls without CHD
Number of subjects: 88700
Study: 33666187

Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg thrice daily for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Famciclovir 500 mg thrice daily for 7 days
Number of subjects: 60
Study: 35275761

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline (without CPAP)
Number of subjects: 16
Study: 34508090

Group type: EXPERIMENTAL
Intervention: Pharm-TCR (low-carbohydrate <50 g, energy-restricted diet 850-1100 kcal/day)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Pharm-TCR
Number of subjects: 188

Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 188
Study: 32223113

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3604

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 3604
Study: 35595373

Group type: EXPERIMENTAL
Intervention: Integrated Specialty Palliative Care (SPC)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study: 32514677

Group type: EXPERIMENTAL
Intervention: Core stability exercises in addition to conventional physical therapy (PT) for 3 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional physical therapy (PT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Core stability exercises in addition to conventional physical therapy (PT)
Number of subjects: 33
Study: 34729862

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen therapy (HFNC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Venturi mask (VM) therapy
Number of subjects: 24
Study: 33892331

Group type: EXPERIMENTAL
Intervention: Repeat attenders
Number of subjects: 42

Group type: COMPARATOR
Intervention: Single attenders
Number of subjects: 42
Study: 32245745

Group type: EXPERIMENTAL
Intervention: Dresden bone-anchored expander
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional hyrax expander
Number of subjects: 29
Study: 35073825

Group type: EXPERIMENTAL
Intervention: Walking training prescribed at 80% of 6MWT average speed
Number of subjects: 11